Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Licenses MedImmune's Reverse Genetics IP to Develop Flu Vaccine Strains

NEW YORK (GenomeWeb News) — MedImmune yesterday said it has licensed its reverse genetics intellectual property to Novartis to help the drug maker develop new influenza vaccine strains.
 
Terms of the deal call for MedImmune to receive an upfront payment from Novartis, as well as the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.
 
Reverse genetics uses segments of viral DNA to create viruses. The method could be particularly useful when working with prospective pandemic flu vaccines because it obviates the need to work directly with potentially highly infectious strains of the virus, according to MedImmune.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.